GSK to buy food allergy drug maker RAPT in $2.2bn deal
US-based biotech firm is developing treatment for allergies such as nuts, milk and eggs in children and adultsBusiness live – latest updatesGSK, the UK’s second-biggest drugmaker, has unveiled a $2.2bn...
By Julia Kollewe · The Guardian World
US-based biotech firm is developing treatment for allergies such as nuts, milk and eggs in children and adults Business live – latest updates GSK, the UK’s second-biggest drugmaker, has unveiled a $2.2bn (£1.6bn) deal to acquire a Californian biotech company which owns a drug that aims to protect against severe food allergies such as nuts, milk and eggs. It is the first large deal announced by GSK’s new chief executive, Luke Miels , who joined the London-based company in 2017 as chief commercial officer and took the reins from Emma Walmsley at the start of the year. Continue reading...